Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT06161051 | Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States | completed | — | 287 | Novartis PharmaceuticalsINDUSTRY | 1 |
| Dec 7, 2023 |
| clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-3) | completed | Phase 3 | 726 | Novartis PharmaceuticalsINDUSTRY | 30 | Nov 30, 2023 | clinicaltrials |
| NCT06148493 | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | completed | — | 425 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 28, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | completed | Phase 2 | 206 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 21, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT03626545 | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy(CANOPY-2) | terminated | Phase 3 | 245 | Novartis PharmaceuticalsINDUSTRY | 26 | Aug 21, 2023 | clinicaltrials |
| NCT05734053 | Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line(NOFRETETE) | completed | — | 222 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05982886 | Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer | completed | — | 1,093 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05984615 | Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients | completed | — | 1,961 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer(AdvanTIG-211) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT05918809 | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings | completed | — | 1,031 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT05893836 | Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia | completed | — | 555 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04547946 | Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) | completed | — | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT05874817 | Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | completed | — | 17,517 | Novartis PharmaceuticalsINDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT05848219 | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib | terminated | — | 543 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT00272987 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | terminated | Phase 3 | 63 | Novartis PharmaceuticalsINDUSTRY | 2 | Apr 28, 2023 | clinicaltrials |
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT05816720 | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) | completed | — | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05806268 | Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients | completed | — | 214 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05611216 | Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation | completed | — | 164 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05796726 | Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations(RECAP) | completed | — | 260 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00251433 | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | terminated | Phase 1 | 53 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 31, 2023 | clinicaltrials |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 9, 2023 | clinicaltrials |
| NCT02452268 | A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers | terminated | Phase 1 | 83 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT02753686 | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy(Treat ER+ight) | completed | — | 440 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT00281658 | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | completed | Phase 3 | 444 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT05714371 | Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | completed | — | 618 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | terminated | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT03710564 | Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections(MERLIN) | terminated | Phase 3 | 535 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 30, 2023 | clinicaltrials |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | completed | Phase 1 | 298 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 11, 2023 | clinicaltrials |
| NCT05675683 | Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib | completed | — | 68 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 21, 2022 | clinicaltrials |
| NCT05619978 | French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients | completed | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05476562 | Study Conducted Among Patients With CML | completed | — | 3,234 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05488613 | Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) | completed | — | 81 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials